| Dr Christian Joseph Fidler, MD | |
|
1200 Old York Rd, Suite 1 Widener, Abington, PA 19001-3720 | |
| (215) 481-2400 | |
| (215) 481-7438 |
| Full Name | Dr Christian Joseph Fidler |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 18 Years |
| Location | 1200 Old York Rd, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396937835 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD436672 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Jefferson University Hospital | Philadelphia, PA | Hospital |
| Abington Memorial Hospital | Abington, PA | Hospital |
| Abington Health Lansdale Hospital | Lansdale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Abington Memorial Hospital | 3274437736 | 528 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.
Health Club Media Network (HCMN), the nation's largest provider of advertising and marketing opportunities for national brands in health clubs, announced today that one of the fitness industry's most renowned brands, Crunch, has joined its network.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Entity Name | Amh Medical Staff Service Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356384457 PECOS PAC ID: 9830003813 Enrollment ID: O20031114000011 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.
Health Club Media Network (HCMN), the nation's largest provider of advertising and marketing opportunities for national brands in health clubs, announced today that one of the fitness industry's most renowned brands, Crunch, has joined its network.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730122789 PECOS PAC ID: 3274437736 Enrollment ID: O20040325000316 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.
Health Club Media Network (HCMN), the nation's largest provider of advertising and marketing opportunities for national brands in health clubs, announced today that one of the fitness industry's most renowned brands, Crunch, has joined its network.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christian Joseph Fidler, MD 1200 Old York Rd, Suite 1 Widener, Abington, PA 19001-3720 Ph: (215) 481-2400 | Dr Christian Joseph Fidler, MD 1200 Old York Rd, Suite 1 Widener, Abington, PA 19001-3720 Ph: (215) 481-2400 |
News Archive
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.
The largest study to date of the use of acute care medical services by people with sickle cell disease found four of every 10 had to return to the hospital within 30 days of a previous hospitalization or go to the emergency department for treatment of pain, according to a new study funded in part by HHS' Agency for Healthcare Research and Quality.
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.
Health Club Media Network (HCMN), the nation's largest provider of advertising and marketing opportunities for national brands in health clubs, announced today that one of the fitness industry's most renowned brands, Crunch, has joined its network.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
› Verified 9 days ago
Dr. Shaili Nepal, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2191 Fax: 215-481-3411 | |
Muhammad Arslan Asghar Cheema, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2222 Fax: 215-481-4361 | |
Margaret Mack, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Joseph Guererri Crocetti Jr., DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 | |
Dr. Joseph Mcallister, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Ste 113, Abington, PA 19001 Phone: 215-517-1180 | |
William L. Ward, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd, Suite 121, Abington, PA 19001 Phone: 215-517-1200 Fax: 215-517-1219 | |
Rebecca Jane Fallis, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1235 Old York Rd Ste 220, Abington, PA 19001 Phone: 215-481-6350 Fax: 215-481-4237 |